Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

o shown clinical activity in a range of skeletal diseases, including bone metastasis, Paget's disease and osteoporosis. An oral dosing regimen offers the potential to exploit the advantages of this compound, which include broad potential activity and convenient administration.

Tesetaxel

Tesetaxel, an oral taxane that is the latest addition to the Genta oncology portfolio, was recently obtained via in-licensing of its worldwide rights. Tesetaxel was specifically developed to avoid key problems associated with other taxanes (such as paclitaxel [Taxol(R); Bristol Myers Squibb] and docetaxel [Taxotere(R); sanofi Aventis]), including severe infusion reactions, peripheral neuropathy, and acquired drug resistance. More than 250 patients worldwide have received tesetaxel, and the drug has demonstrated anticancer activity in several clinical trials. Due to the occurrence of several fatalities related to neutropenia, the drug is currently on clinical hold in the U.S. Based upon guidance from FDA, Genta has worked with the former sponsor to develop a strategy that is intended to lift the clinical hold, thereby enabling clinical testing to resume. If further studies document efficacy and safety, tesetaxel offers substantial opportunities to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes.

C-myb Antisense

An antisense drug directed against c-myb, a master regulatory proto- oncogene, is the Company's earliest stage clinical program. In 2007, a new dose-ranging Phase 1 trial of c-myb antisense was initiated at the University of Pennsylvania. The trial is currently open to accrual and is expected to be completed later this year after identification of the MTD.

Financial Information

The Company reported a net loss of $1.7 million or $0.06 per share for the fourth quarter of 2007, compared with a net loss of $17.3 million or $0.68 per share for the fourth quarter of 2006. For the year en
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... face of regulatory and marketplace changes. CI leaders who ... In a new Best Practices, LLC ... host of actionable insights, including: - Use ... cheaper than primary research - Internal staff ...
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... 26 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Pharmaceuticals, Inc. (Huxley), which has rights to a ... the rare autoimmune disease Lambert Eaton Myasthenic Syndrome ... Products for Human Use of the European Medicines ...
... PINNACLE Network (TM) Links Thousands of Clinical ... Excellence , WASHINGTON, Oct. 26 The ... of the PINNACLE Network(TM), the first-ever registry-based cardiovascular ... each other and to the ACC,s National Cardiovascular ...
Cached Medicine Technology:BioMarin Acquires Huxley Pharmaceuticals, Inc. 2BioMarin Acquires Huxley Pharmaceuticals, Inc. 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 4BioMarin Acquires Huxley Pharmaceuticals, Inc. 5BioMarin Acquires Huxley Pharmaceuticals, Inc. 6American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 2American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 3
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... Los Angeles (PRWEB) September 01, 2014 ... fluctuations. These hormonal daily changes begin as early ... most of their lives negotiating the ups and downs ... skinny or thin or even healthy sizes seems to ... daily. As a woman in her 40's begin ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... 2014 The National Association of Hispanic ... Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, ... Academy of Nursing. They will be inducted with Immediate ... whose induction we reported last May. , Our three ... the 2014 American Academy of Nursing Policy Conference in ...
(Date:9/1/2014)... 01, 2014 In honor of National Take Your ... Animal Emergency & Referral Center of Minnesota (AERC) is offering a ... for their cats. , Many people don’t take their cat to ... a hassle,” but they wouldn’t decide not to take their kid ... cavity. The same goes for pets. Just like people want their ...
Breaking Medicine News(10 mins):Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... 14, 2012) A new study by University of ... for basal-like breast cancer, commonly known as triple-negative breast ... resistance to chemotherapy and occurs at women at a ... program that promotes cell migration and reduces adhesion between ...
... through colonoscopy is an effective treatment for recurrent ... study in Gastroenterology , the official journal of ... this study does not appear to be greater than ... itself seems to be a rather safe procedure. CDI ...
... large international study indicates that anti-inflammatory drugs may become ... disease (CHD), the leading global cause of death. In ... heart disease, the researchers used the Cardiochip, a gene ... researcher in the Center for Applied Genomics at The ...
... By Carina Storrs HealthDay Reporter , TUESDAY, March ... lot to do with factors like race, age and where ... patterns, according to a new study. Researchers analyzed food ... aged 45 and older in the continental United States, with ...
... Scientists have identified a new compound that rapidly kills ... liver cancer and fifth most common cancer worldwide, while ... (FQI1), works by inhibiting an oncogene originally discovered by ... Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey ...
... 10 (HealthDay News) -- In people with a concussion, ... injury symptoms disappear, researchers have found. A test ... help improve treatment for people with a concussion, according ... led the study as a graduate student at the ...
Cached Medicine News:Health News:New study shows promise for developing new treatments for breast cancer 2Health News:A new treatment option for Clostridium difficile: Fecal transplantation 2Health News:Gene chip invented by CHOP scientist pinpoints new target to prevent heart disease 2Health News:Race, Location Big Factors in American Diets 2Health News:Race, Location Big Factors in American Diets 3Health News:New compound discovered that rapidly kills liver cancer 2Health News:'Delayed Reactions' May Outlast Other Concussion Effects 2
Toxoplasma IgG II ELISA...
ELISA kit for CMV CAP M....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Medicine Products: